Cargando…
Effect of disease‐modifying agents and their association with mortality in multi‐morbid patients with heart failure with reduced ejection fraction
AIMS: An increasing proportion of patients with heart failure with reduced ejection fraction (HFrEF) have co‐morbidities. The effect of these co‐morbidities on modes of death and the effect of disease‐modifying agents in multi‐morbid patients is unknown. METHODS AND RESULTS: We performed a prospecti...
Autores principales: | Straw, Sam, McGinlay, Melanie, Relton, Samuel D., Koshy, Aaron O., Gierula, John, Paton, Maria F., Drozd, Michael, Lowry, Judith E, Cole, Charlotte, Cubbon, Richard M, Witte, Klaus K., Kearney, Mark T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754757/ https://www.ncbi.nlm.nih.gov/pubmed/32924331 http://dx.doi.org/10.1002/ehf2.12978 |
Ejemplares similares
-
Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2022) -
Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2021) -
Prioritizing symptom management in the treatment of chronic heart failure
por: Koshy, Aaron O., et al.
Publicado: (2020) -
Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity?
por: McGinlay, Melanie, et al.
Publicado: (2022) -
Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
por: Gierula, John, et al.
Publicado: (2022)